2013 ACCF/AHA Guideline for the Management of Heart Failure

Journal of the American College of Cardiology ? 2013 by the American College of Cardiology Foundation and the American Heart Association, Inc. Published by Elsevier Inc.

PRACTICE GUIDELINE

Vol. 62, No. 16, 2013 ISSN 0735-1097/$36.00

2013 ACCF/AHA Guideline for the

Management of Heart Failure

A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines

Developed in Collaboration With the American College of Chest Physicians, Heart Rhythm Society and International Society for Heart and Lung Transplantation

Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation

WRITING COMMITTEE MEMBERS*

Clyde W. Yancy, MD, MSc, FACC, FAHA, Chairyz; Mariell Jessup, MD, FACC, FAHA, Vice Chair*y; Biykem Bozkurt, MD, PhD, FACC, FAHAy; Javed Butler, MBBS, FACC, FAHA*y; Donald E. Casey, Jr, MD, MPH, MBA, FACP, FAHAx;

Mark H. Drazner, MD, MSc, FACC, FAHA*y; Gregg C. Fonarow, MD, FACC, FAHA*y; Stephen A. Geraci, MD, FACC, FAHA, FCCPjj; Tamara Horwich, MD, FACCy; James L. Januzzi, MD, FACC*y; Maryl R. Johnson, MD, FACC, FAHA{; Edward K. Kasper, MD, FACC, FAHAy; Wayne C. Levy, MD, FACC*y;

Frederick A. Masoudi, MD, MSPH, FACC, FAHAy#; Patrick E. McBride, MD, MPH, FACC**; John J. V. McMurray, MD, FACC*y; Judith E. Mitchell, MD, FACC, FAHAy;

Pamela N. Peterson, MD, MSPH, FACC, FAHAy; Barbara Riegel, DNSc, RN, FAHAy; Flora Sam, MD, FACC, FAHAy; Lynne W. Stevenson, MD, FACC*y; W. H. Wilson Tang, MD, FACC*y; Emily J. Tsai, MD, FACCy; Bruce L. Wilkoff, MD, FACC, FHRS*yy

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information. yACCF/AHA representative. zACCF/AHA Task Force on Practice Guidelines liaison. xAmerican College of Physicians representative. jjAmerican College of Chest Physicians representative. {International Society for Heart and Lung Transplantation representative. #ACCF/AHA Task Force on Performance Measures liaison. **American Academy of Family Physicians representative. yyHeart Rhythm Society representative. zzFormer Task Force member during this writing effort.

This document was approved by the American College of Cardiology Foundation Board of Trustees and the American Heart Association Science Advisory and Coordinating Committee in May 2013.

The American College of Cardiology Foundation requests that this document be cited as follows: Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147?239.

This article has been copublished in Circulation. Copies: This document is available on the World Wide Web sites of the American College of Cardiology () and the American Heart Association (my.). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@. Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier's permission department at healthpermissions@.

Downloaded From: on 12/10/2013

e148

Yancy et al. 2013 ACCF/AHA Heart Failure Guideline: Full Text

JACC Vol. 62, No. 16, 2013 October 15, 2013:e147?239

ACCF/AHA TASK FORCE MEMBERS

Jeffrey L. Anderson, MD, FACC, FAHA, Chair; Alice K. Jacobs, MD, FACC, FAHA, Immediate Past Chairzz;

Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect; Nancy M. Albert, PhD, CCNS, CCRN, FAHA; Biykem Bozkurt, MD, PhD, FACC, FAHA;

Ralph G. Brindis, MD, MPH, MACC; Mark A. Creager, MD, FACC, FAHAzz; Lesley H. Curtis, PhD; David DeMets, PhD; Robert A. Guyton, MD, FACC;

Judith S. Hochman, MD, FACC, FAHA; Richard J. Kovacs, MD, FACC, FAHA; Frederick G. Kushner, MD, FACC, FAHAzz; E. Magnus Ohman, MD, FACC;

Susan J. Pressler, PhD, RN, FAAN, FAHA; Frank W. Sellke, MD, FACC, FAHA; Win-Kuang Shen, MD, FACC, FAHA; William G. Stevenson, MD, FACC, FAHAzz;

Clyde W. Yancy, MD, MSc, FACC, FAHAzz

TABLE OF CONTENTS

Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e150

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e152

1.1. Methodology and Evidence Review . . . . . . . . . e152 1.2. Organization of the Writing Committee . . . . . e152 1.3. Document Review and Approval . . . . . . . . . . . . e152 1.4. Scope of This Guideline With Reference to

Other Relevant Guidelines or Statements . . . e153 2. Definition of HF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e153

2.1. HF With Reduced EF (HFrEF) . . . . . . . . . . . . . . . . e153 2.2. HF With Preserved EF (HFpEF) . . . . . . . . . . . . . . e154 3. HF Classifications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e155

4. Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e156

4.1. Mortality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e156 4.2. Hospitalizations . . . . . . . . . . . . . . . . . . . . . . . . . . . . e156 4.3. Asymptomatic LV Dysfunction . . . . . . . . . . . . . . e156 4.4. Health-Related Quality of Life and

Functional Status . . . . . . . . . . . . . . . . . . . . . . . . . . e156 4.5. Economic Burden of HF . . . . . . . . . . . . . . . . . . . . . e157 4.6. Important Risk Factors for HF (Hypertension,

Diabetes Mellitus, Metabolic Syndrome, and Atherosclerotic Disease) . . . . . . . . . . . . . . . . . . . e157 5. Cardiac Structural Abnormalities and Other Causes of HF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e157

5.1. Dilated Cardiomyopathies . . . . . . . . . . . . . . . . . . e157 5.1.1. Definition and Classification of Dilated Cardiomyopathies . . . . . . . . . . . . . . . . . . . . . . e157 5.1.2. Epidemiology and Natural History of DCM . . . . . . . . . . . . . . . . . . . . . . . e157

5.2. Familial Cardiomyopathies . . . . . . . . . . . . . . . . . . e158 5.3. Endocrine and Metabolic Causes of

Cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . e158 5.3.1. Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e158 5.3.2. Diabetic Cardiomyopathy . . . . . . . . . . . . . . . e158

5.3.3. Thyroid Disease . . . . . . . . . . . . . . . . . . . . . . . e158 5.3.4. Acromegaly and Growth Hormone

Deficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . e158 5.4. Toxic Cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . e159

5.4.1. Alcoholic Cardiomyopathy . . . . . . . . . . . . . . e159 5.4.2. Cocaine Cardiomyopathy . . . . . . . . . . . . . . . . e159 5.4.3. Cardiotoxicity Related to Cancer Therapies . . e159 5.4.4. Other Myocardial Toxins and Nutritional

Causes of Cardiomyopathy . . . . . . . . . . . . . . e159 5.5. Tachycardia-Induced Cardiomyopathy . . . . . . . e159 5.6. Myocarditis and Cardiomyopathies Due to

Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e159 5.6.1. Myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . e159 5.6.2. Acquired Immunodeficiency Syndrome . . . . e160 5.6.3. Chagas Disease . . . . . . . . . . . . . . . . . . . . . . . . e160 5.7. Inflammation-Induced Cardiomyopathy: Noninfectious Causes . . . . . . . . . . . . . . . . . . . . . . e160 5.7.1. Hypersensitivity Myocarditis . . . . . . . . . . . . . e160 5.7.2. Rheumatological/Connective Tissue

Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e160 5.8. Peripartum Cardiomyopathy . . . . . . . . . . . . . . . . e160 5.9. Cardiomyopathy Caused By Iron Overload . . . e160 5.10. Amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e161 5.11. Cardiac Sarcoidosis . . . . . . . . . . . . . . . . . . . . . . . e161 5.12. Stress (Takotsubo) Cardiomyopathy . . . . . . . e161

6. Initial and Serial Evaluation of the HF Patient . . e161

6.1. Clinical Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . e161 6.1.1. History and Physical Examination: Recommendations . . . . . . . . . . . . . . . . . . . . . . e161 6.1.2. Risk Scoring: Recommendation . . . . . . . . . . e161

6.2. Diagnostic Tests: Recommendations . . . . . . . . e163 6.3. Biomarkers: Recommendations . . . . . . . . . . . . . e163

6.3.1. Natriuretic Peptides: BNP or NT-proBNP . . e164 6.3.2. Biomarkers of Myocardial Injury: Cardiac

Troponin T or I . . . . . . . . . . . . . . . . . . . . . . . e164 6.3.3. Other Emerging Biomarkers . . . . . . . . . . . . . e165 6.4. Noninvasive Cardiac Imaging: Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . e165 6.5. Invasive Evaluation: Recommendations . . . . . e167 6.5.1. Right-Heart Catheterization . . . . . . . . . . . . . e167 6.5.2. Left-Heart Catheterization . . . . . . . . . . . . . . e168 6.5.3. Endomyocardial Biopsy . . . . . . . . . . . . . . . . . e168

Downloaded From: on 12/10/2013

JACC Vol. 62, No. 16, 2013 October 15, 2013:e147?239

7. Treatment of Stages A to D . . . . . . . . . . . . . . . . . . . . e168

7.1. Stage A: Recommendations . . . . . . . . . . . . . . . . e168 7.1.1. Recognition and Treatment of Elevated Blood Pressure . . . . . . . . . . . . . . . . . e168 7.1.2. Treatment of Dyslipidemia and Vascular Risk . . . . . . . . . . . . . . . . . . . . . . . . . . e168 7.1.3. Obesity and Diabetes Mellitus . . . . . . . . . . . e168 7.1.4. Recognition and Control of Other Conditions That May Lead to HF . . . . . . . e169

7.2. Stage B: Recommendations . . . . . . . . . . . . . . . . e169 7.2.1. Management Strategies for Stage B . . . . . . . e170

7.3. Stage C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e171 7.3.1. Nonpharmacological Interventions . . . . . . . . e171 7.3.1.1. EDUCATION: RECOMMENDATION . . . . . . . . . . e171 7.3.1.2. SOCIAL SUPPORT . . . . . . . . . . . . . . . . . . . . e171 7.3.1.3. SODIUM RESTRICTION: RECOMMENDATION . . . e171

7.3.1.4. TREATMENT OF SLEEP DISORDERS:

RECOMMENDATION . . . . . . . . . . . . . . . . . . e172 7.3.1.5. WEIGHT LOSS . . . . . . . . . . . . . . . . . . . . . . e172

7.3.1.6. ACTIVITY, EXERCISE PRESCRIPTION,

AND CARDIAC REHABILITATION:

RECOMMENDATIONS . . . . . . . . . . . . . . . . . . e172 7.3.2. Pharmacological Treatment for Stage C

HFrEF: Recommendations . . . . . . . . . . . . . . e172 7.3.2.1. DIURETICS: RECOMMENDATION . . . . . . . . . . . e173 7.3.2.2. ACE INHIBITORS: RECOMMENDATION . . . . . . . e174 7.3.2.3. ARBS: RECOMMENDATIONS . . . . . . . . . . . . . e175 7.3.2.4. BETA BLOCKERS: RECOMMENDATION . . . . . . . e176

7.3.2.5. ALDOSTERONE RECEPTOR ANTAGONISTS:

RECOMMENDATIONS . . . . . . . . . . . . . . . . . . e177

7.3.2.6. HYDRALAZINE AND ISOSORBIDE DINITRATE:

RECOMMENDATIONS . . . . . . . . . . . . . . . . . . e179 7.3.2.7. DIGOXIN: RECOMMENDATION . . . . . . . . . . . . e179 7.3.2.8. OTHER DRUG TREATMENT . . . . . . . . . . . . . . e180

7.3.2.8.1. ANTICOAGULATION:

RECOMMENDATIONS . . . . . . . . . e180 7.3.2.8.2. STATINS: RECOMMENDATION . . . e181

7.3.2.8.3. OMEGA-3 FATTY ACIDS:

RECOMMENDATION . . . . . . . . . . e181

7.3.2.9. DRUGS OF UNPROVEN VALUE OR THAT MAY

WORSEN HF: RECOMMENDATIONS . . . . . . . . . e182

7.3.2.9.1. NUTRITIONAL SUPPLEMENTS AND

HORMONAL THERAPIES . . . . . . . e182 7.3.2.9.2. ANTIARRHYTHMIC AGENTS . . . . . e182

7.3.2.9.3. CALCIUM CHANNEL BLOCKERS:

RECOMMENDATION . . . . . . . . . . e182

7.3.2.9.4. NONSTEROIDAL ANTI-

INFLAMMATORY DRUGS . . . . . . . e182 7.3.2.9.5. THIAZOLIDINEDIONES . . . . . . . . e182 7.3.3. Pharmacological Treatment for Stage C HFpEF: Recommendations . . . . . . . . . . . . . . e183 7.3.4. Device Therapy for Stage C HFrEF: Recommendations . . . . . . . . . . . . . . . . . . . . . . e183

7.3.4.1. IMPLANTABLE CARDIOVERTER-

DEFIBRILLATOR . . . . . . . . . . . . . . . . . . . . . e186

7.3.4.2. CARDIAC RESYNCHRONIZATION

THERAPY . . . . . . . . . . . . . . . . . . . . . . . . .e188 7.4. Stage D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e189

7.4.1. Definition of Advanced HF . . . . . . . . . . . . . e189 7.4.2. Important Considerations in Determining

If the Patient Is Refractory . . . . . . . . . . . . . . e189 7.4.3. Water Restriction: Recommendation . . . . . . e190 7.4.4. Inotropic Support: Recommendations . . . . . e190 7.4.5. Mechanical Circulatory Support:

Recommendations . . . . . . . . . . . . . . . . . . . . . . e191 7.4.6. Cardiac Transplantation:

Recommendation . . . . . . . . . . . . . . . . . . . . . . e192

Yancy et al. 2013 ACCF/AHA Heart Failure Guideline: Full Text

e149

8. The Hospitalized Patient . . . . . . . . . . . . . . . . . . . . . . . e193

8.1. Classification of Acute Decompensated HF . . . . . . . . . . . . . . . . . . . . . . . . . e193

8.2. Precipitating Causes of Decompensated HF: Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . e194

8.3. Maintenance of GDMT During Hospitalization: Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . e195

8.4. Diuretics in Hospitalized Patients: Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . e195

8.5. Renal Replacement TherapydUltrafiltration: Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . e196

8.6. Parenteral Therapy in Hospitalized HF: Recommendation . . . . . . . . . . . . . . . . . . . . . . . . . . e196

8.7. Venous Thromboembolism Prophylaxis in Hospitalized Patients: Recommendation . . . . . . . . . . . . . . . . . . . . . . . . . . e197

8.8. Arginine Vasopressin Antagonists: Recommendation . . . . . . . . . . . . . . . . . . . . . . . . . . e198

8.9. Inpatient and Transitions of Care: Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . e198

9. Important Comorbidities in HF . . . . . . . . . . . . . . . . . e200

9.1. Atrial Fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . e200 9.2. Anemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e201 9.3. Depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e203 9.4. Other Multiple Comorbidities . . . . . . . . . . . . . . . e203

10. Surgical/Percutaneous/Transcatheter Interventional Treatments of HF: Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . e204

11. Coordinating Care for Patients With Chronic HF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e205

11.1. Coordinating Care for Patients With Chronic HF: Recommendations . . . . . . . . . . e205

11.2. Systems of Care to Promote Care Coordination for Patients With Chronic HF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e207

11.3. Palliative Care for Patients With HF . . . . . e207

12. Quality Metrics/Performance Measures: Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . e207

13. Evidence Gaps and Future Research Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e208

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e210

Appendix 1. Author Relationships With Industry and Other Entities (Relevant) . . . . . . . . . . . . . . . . . . . . . . . . . . . e232

Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) . . . . . . . . . . . . . . . . . . . . . . . . . . . e235

Appendix 3. Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . e239

Downloaded From: on 12/10/2013

e150

Yancy et al. 2013 ACCF/AHA Heart Failure Guideline: Full Text

Preamble

The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist clinicians in selecting the best management strategy for an individual patient. Moreover, clinical practice guidelines can provide a foundation for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools.

The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly produced guidelines in the area of cardiovascular disease since 1980. The ACCF/AHA Task Force on Practice Guidelines (Task Force), charged with developing, updating, and revising practice guidelines for cardiovascular diseases and procedures, directs and oversees this effort. Writing committees are charged with regularly reviewing and evaluating all available evidence to develop balanced, patient-centric recommendations for clinical practice.

Experts in the subject under consideration are selected by the ACCF and AHA to examine subject-specific data and write guidelines in partnership with representatives from other medical organizations and specialty groups. Writing committees are asked to perform a literature review; weigh the strength of evidence for or against particular tests, treatments, or procedures; and include estimates of expected outcomes where such data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that may influence the choice of tests or therapies are considered. When available, information from studies on cost is considered, but data on efficacy and outcomes constitute the primary basis for the recommendations contained herein.

In analyzing the data and developing recommendations and supporting text, the writing committee uses evidence-based methodologies developed by the Task Force (1). The Class of Recommendation (COR) is an estimate of the size of the treatment effect considering risks versus benefits in addition to evidence and/or agreement that a given treatment or procedure is or is not useful/effective or in some situations may cause harm. The Level of Evidence (LOE) is an estimate of the certainty or precision of the treatment effect. The writing committee reviews and ranks evidence supporting each recommendation with the weight of evidence ranked as LOE A, B, or C according to specific definitions that are included in Table 1. Studies are identified as observational, retrospective, prospective, or randomized where appropriate. For certain conditions for which inadequate data are available,

JACC Vol. 62, No. 16, 2013 October 15, 2013:e147?239

recommendations are based on expert consensus and clinical experience and are ranked as LOE C. When recommendations at LOE C are supported by historical clinical data, appropriate references (including clinical reviews) are cited if available. For issues for which sparse data are available, a survey of current practice among the clinicians on the writing committee is the basis for LOE C recommendations and no references are cited. The schema for COR and LOE are summarized in Table 1, which also provides suggested phrases for writing recommendations within each COR. A new addition to this methodology is separation of the Class III recommendations to delineate whether the recommendation is determined to be of "no benefit" or is associated with "harm" to the patient. In addition, in view of the increasing number of comparative effectiveness studies, comparator verbs and suggested phrases for writing recommendations for the comparative effectiveness of one treatment or strategy versus another have been added for COR I and IIa, LOE A or B only.

In view of the advances in medical therapy across the spectrum of cardiovascular diseases, the Task Force has designated the term guideline-directed medical therapy (GDMT) to represent optimal medical therapy as defined by ACCF/AHA guideline?recommended therapies (primarily Class I). This new term, GDMT, will be used herein and throughout all future guidelines.

Because the ACCF/AHA practice guidelines address patient populations (and clinicians) residing in North America, drugs that are not currently available in North America are discussed in the text without a specific COR. For studies performed in large numbers of subjects outside North America, each writing committee reviews the potential influence of different practice patterns and patient populations on the treatment effect and relevance to the ACCF/AHA target population to determine whether the findings should inform a specific recommendation.

The ACCF/AHA practice guidelines are intended to assist clinicians in clinical decision making by describing a range of generally acceptable approaches to the diagnosis, management, and prevention of specific diseases or conditions. The guidelines attempt to define practices that meet the needs of most patients in most circumstances. The ultimate judgment regarding care of a particular patient must be made by the clinician and patient in light of all the circumstances presented by that patient. As a result, situations may arise for which deviations from these guidelines may be appropriate. Clinical decision making should involve consideration of the quality and availability of expertise in the area where care is provided. When these guidelines are used as the basis for regulatory or payer decisions, the goal should be improvement in quality of care. The Task Force recognizes that situations arise in which additional data are needed to inform patient care more effectively; these areas will be identified within each respective guideline when appropriate.

Prescribed courses of treatment in accordance with these recommendations are effective only if followed. Because lack of patient understanding and adherence may adversely affect

Downloaded From: on 12/10/2013

JACC Vol. 62, No. 16, 2013 October 15, 2013:e147?239

Yancy et al. 2013 ACCF/AHA Heart Failure Guideline: Full Text

e151

Table 1. Applying Classification of Recommendation and Level of Evidence

A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use.

yFor comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

outcomes, clinicians should make every effort to engage the patient's active participation in prescribed medical regimens and lifestyles. In addition, patients should be informed of the risks, benefits, and alternatives to a particular treatment and be involved in shared decision making whenever feasible, particularly for COR IIa and IIb, for which the benefit-to-risk ratio may be lower.

The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among

the members of the writing committee. All writing committee members and peer reviewers of the guideline are required to disclose all current healthcare-related relationships, including those existing 12 months before initiation of the writing effort. In December 2009, the ACCF and AHA implemented a new policy for relationship with industry and other entities (RWI) that requires the writing committee chair plus a minimum of 50% of the writing committee to have no relevant RWI (Appendix 1 includes the ACCF/AHA definition of relevance). These statements are reviewed by the Task Force and

Downloaded From: on 12/10/2013

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download